全身免疫炎症指数(SII)及肝纤维化指标(GPR)在肝细胞癌中的研究进展
Research Progress on Systemic Immune Inflammation Index (SII) and Liver Fibrosis Index (GPR) in HepatocellularCarcinoma
摘要: 肝细胞癌(HCC)是原发性肝癌(PHC)中最常见的一种类型，是一种高度异质性、复杂性和侵袭性的恶性肿瘤。目前根治性的肝切除术依旧是肝细胞癌的最主要的治疗方法，然而术后患者的生存率以及肿瘤的高复发率依旧存在很大问题。近些年来，全身免疫炎症指数(systemic immune-inflammation index)和γ-谷氨酰转肽酶/血小板比值(GPR)等已经成为HCC研究的热点问题。SII作为一种全身炎症反应的评价指标，现已被证实与HCC患者的预后相关。γ-谷氨酰转肽酶、血小板也被证实是肝细胞癌的独立危险因素。本文将从全身免疫炎症指数SII和γ-谷氨酰转肽酶/血小板比值GPR指标出发，与肝细胞癌相关联进行系统性综述，以便更好地了解相关指标在HCC患者预后中的应用和作用。
Abstract: Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer (PHC). It is a highly heterogeneous, complex and aggressive malignancy. At present, radical hepatectomy is still the main treatment method for hepatocellular carcinoma; however, the survival rate of postopera-tive patients and the high recurrence rate of tumors are still a big problem. In recent years, sys-temic immunoinflammatory index and gamma-glutamyl transpeptidase/platelet ratio (GPR) have become hot topics in HCC research. SII, as an evaluation indicator of systemic inflammatory re-sponse, has been confirmed to be associated with the prognosis of HCC patients. Gamma-glutamyl transpeptidase and platelets have also been shown to be independent risk factors for hepatocellu-lar carcinoma. Based on systemic immunoinflammatory index SII and gamma-glutamyl transpep-tidase/platelet ratio GPR indicators, this paper will conduct a systematic review of their association with hepatocellular carcinoma, so as to better understand the application and role of relevant indi-cators in the prognosis of HCC patients.
文章引用：韩毅, 汪笑楠, 王宏宾. 全身免疫炎症指数(SII)及肝纤维化指标(GPR)在肝细胞癌中的研究进展[J]. 临床医学进展, 2023, 13(7): 11529-11534. https://doi.org/10.12677/ACM.2023.1371612

参考文献

[1] 原发性肝癌诊疗指南(2022年版) [J]. 肿瘤综合治疗电子杂志, 2022, 8(2): 16-53.
[2] 董菁菁, 王允野. γ-谷氨酰转肽酶与血小板比值指数与乙肝相关肝细胞癌预后的关系[J]. 中国实验诊断学, 2021, 25(6): 860-864.
[3] Cheng, J., Wang, W., Zhang, Y., et al. (2014) Prognostic Role of Pre-Treatment Serum AFP-L3% in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis. PLOS ONE, 9, e87011. [Google Scholar] [CrossRef] [PubMed]
[4] Tandon, P. and Garcia-Tsao, G. (2009) Prognostic Indicators in Hepatocellular Carcinoma: A Systematic Review of 72 Studies. Liver International: Official Journal of the International Association for the Study of the Liver, 29, 502-510. [Google Scholar] [CrossRef] [PubMed]
[5] Yang, Z., Ye, P., Xu, Q., et al. (2015) Elevation of Serum GGT and LDH Levels, Together with Higher BCLC Staging Are Associated with Poor Overall Survival from Hepato-cellular Carcinoma: A Retrospective Analysis. Discovery Medicine, 19, 409-418.
[6] 卿明. ALRI和NLR在乙肝相关肝细胞癌切除预后评估中的价值[D]: [硕士学位论文]. 泸州: 西南医科大学, 2019.
[7] Yao, M., Zhao, J. and Lu, F. (2016) Alpha-Fetoprotein Still Is a Valuable Diagnostic and Prognosis Predicting Biomarker in Hepatitis B Virus In-fection-Related Hepatocellular Carcinoma. Oncotarget, 7, 3702-3708. [Google Scholar] [CrossRef] [PubMed]
[8] Jian, Z., Lei, Y., Gao, X., et al. (2011) Plasma microRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma. Journal of Clinical Oncology, 29, 4781-4788. [Google Scholar] [CrossRef] 
[9] Fan, J., Guo, W., Sun, Y.F., et al. (2018) Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis and Therapeutic Response Evaluation in Hepatocellular Carcinoma. Clinical Cancer Research, 24, 2203-2213.
[10] Zhou, J., Huang, A. and Yang, X.R. (2016) Liquid Biopsy and Its Po-tential for Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 47, 157-167. [Google Scholar] [CrossRef] [PubMed]
[11] Lemoine, M., Shimakawa, Y., Nayagam, S., et al. (2016) The Gamma-Glutamyl Transpeptidase to Platelet Ratio (GPR) Predicts Significant Liver Fibrosis and Cirrhosis in Patients with Chronic HBV Infection in West Africa. Gut, 65, 1369-1376. [Google Scholar] [CrossRef] [PubMed]
[12] Pang, Q., Xu, X.S., Zhang, J.Y., et al. (2015) FIB-4 as a Prog-nostic Model for Patients with Hepatitis B-Associated Hepatocellular Carcinoma. Hepatology, 62, 1325-1326. [Google Scholar] [CrossRef] [PubMed]
[13] Pang, Q., Bi, J.B., Xu, X.S., et al. (2015) King’s Score as a Novel Prog-nostic Model for Patients with Hepatitis B-Associated Hepatocellular Carcinoma. European Journal of Gastroenterology & Hepatology, 27, 1337-1346.
[14] Choi, W.M., Lee, J.H., Ahn, H., et al. (2015) Forns Index Predicts Recurrence and Death in Patients with Hepatitis B-Related Hepatocellular Carcinoma after Curative Resection. Liver International, 35, 1992-2000. [Google Scholar] [CrossRef] [PubMed]
[15] Sierko, E. and Wojtukiewicz, M.Z. (2004) Platelets and Angiogenesis in Malignancy. Seminars in Thrombosis and Hemostasis, 30, 95-108. [Google Scholar] [CrossRef] [PubMed]
[16] Labelle, M., Begum, S. and Hynes, R.O. (2011) Direct Signaling be-tween Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis. Cancer Cell, 20, 576-590. [Google Scholar] [CrossRef] [PubMed]
[17] Bambace, N.M. and Holmes, C.E. (2011) The Platelet Contribution to Cancer Progression. Journal of Thrombosis and Haemostasis: JTH, 9, 237-249. [Google Scholar] [CrossRef] [PubMed]
[18] Ferroni, P., Spila, A., D’alessandro, R., et al. (2011) Plate-let Activation and Vascular Endothelial Growth Factor 165 Release in Hepatocellular Cancer. Clinica Chimica Acta; In-ternational Journal of Clinical Chemistry, 412, 450-454. [Google Scholar] [CrossRef] [PubMed]
[19] Plantureux, L., Crescence, L., Dignat-George, F., et al. (2018) Ef-fects of Platelets on Cancer Progression. Thrombosis Research, 164, S40-S47. [Google Scholar] [CrossRef] [PubMed]
[20] Timp, J.F., Braekkan, S.K., Versteeg, H.H., et al. (2013) Epi-demiology of Cancer-Associated Venous Thrombosis. Blood, 122, 1712-1723. [Google Scholar] [CrossRef] [PubMed]
[21] Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Im-munobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 21, 137-148. [Google Scholar] [CrossRef] [PubMed]
[22] Wu, L., Saxena, S., Awaji, M., et al. (2019) Tumor-Associated Neutrophils in Cancer: Going Pro. Cancers, 11, Article No. 564. [Google Scholar] [CrossRef] [PubMed]
[23] Chan, S.L., Chan, A.W., Chan, A.K., et al. (2017) Systematic Eval-uation of Circulating Inflammatory Markers for Hepatocellular Carcinoma. Liver International: Official Journal of the In-ternational Association for the Study of the Liver, 37, 280-289. [Google Scholar] [CrossRef] [PubMed]
[24] De Larco, J.E., Wuertz, B.R. and Furcht, L.T. (2004) The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 4895-4900. [Google Scholar] [CrossRef] 
[25] Ardi, V.C., Kupriyanova, T.A., Deryugina, E.I., et al. (2007) Human Neutrophils Uniquely Release TIMP-Free MMP-9 to Provide a Potent Catalytic Stimulator of Angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104, 20262-20267. [Google Scholar] [CrossRef] [PubMed]
[26] Hu, B., Yang, X.R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clin-ical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef] 
[27] Pang, Q., Zhou, L., Qu, K., et al. (2018) Validation of In-flammation-Based Prognostic Models in Patients with Hepatitis B-Associated Hepatocellular Carcinoma: A Retrospective Observational Study. European Journal of Gastroenterology & Hepatology, 30, 60-70. [Google Scholar] [CrossRef] 
[28] Hanigan, M.H. (2014) Gamma-Glutamyl Transpeptidase: Redox Regulation and Drug Resistance. Advances in Cancer Research, 122, 103-141. [Google Scholar] [CrossRef] 
[29] Zilkens, C., Friese, J., Köller, M., et al. (2008) Hepatic Failure after Injury—A Common Pathogenesis with Sclerosing Cholangitis? European Journal of Medical Research, 13, 309-313.
[30] Bao, M., Zhu, Q., Aji, T., et al. (2021) Development of Models to Predict Postoperative Complications for Hepatitis B Virus-Related Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article ID: 717826. [Google Scholar] [CrossRef] [PubMed]
[31] Luo, D., Li, H., Hu, J., et al. (2020) Development and Validation of Nomograms Based on Gamma-Glutamyl Transpeptidase to Platelet Ratio for Hepatocellular Carcinoma Patients Reveal Novel Prognostic Value and the Ratio Is Negatively Correlated with P38MAPK Expression. Frontiers in Oncology, 10, Article ID: 548744. [Google Scholar] [CrossRef] [PubMed]
[32] Yang, D., Wu, H., Nong, W., et al. (2021) A New Model Based on Gamma-Glutamyl Transpeptidase to Platelet Ratio (GPR) Predicts Prognostic Outcome after Curative Resection of Soli-tary Hepatocellular Carcinoma. Clinics and Research in Hepatology and Gastroenterology, 45, Article ID: 101509. [Google Scholar] [CrossRef] [PubMed]
[33] Dai, T., Deng, M., Ye, L., et al. (2020) Prognostic Value of Com-bined Preoperative Gamma-Glutamyl Transpeptidase to Platelet Ratio and Fibrinogen in Patients with HBV-Related Hepatocellular Carcinoma after Hepatectomy. American Journal of Translational Research, 12, 2984-2997.

为你推荐